{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:43:42Z","timestamp":1792716222106,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008131","name":"University Hospital Bonn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008131","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jmoldx.2020.04.205","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T13:16:43Z","timestamp":1588252603000},"page":"920-933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood"],"prefix":"10.1016","volume":"22","author":[{"given":"Luka","family":"de Vos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth-Miriam","family":"Koerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4772-7675","authenticated-orcid":false,"given":"Emma G.","family":"Bawden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias A.W.","family":"Holderried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Bootz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Brossart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimo","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2020.04.205_bib1","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib4","doi-asserted-by":"crossref","first-page":"FSO295","DOI":"10.4155\/fsoa-2017-0140","article-title":"Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature","volume":"4","author":"Khier","year":"2018","journal-title":"Future Sci OA"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fmolb.2015.00013","article-title":"Methylation of cell-free circulating DNA in the diagnosis of cancer","volume":"2","author":"Warton","year":"2015","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib6","doi-asserted-by":"crossref","first-page":"e0118195","DOI":"10.1371\/journal.pone.0118195","article-title":"Quantification of cell-free mSHOX2 plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients","volume":"10","author":"Schmidt","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib7","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1097\/JTO.0b013e318220ef9a","article-title":"SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma","volume":"6","author":"Kneip","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib8","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1373\/clinchem.2016.270207","article-title":"Free-circulating methylated DNA in blood for diagnosis, staging, prognosis, and monitoring of head and neck squamous cell carcinoma patients: an observational prospective cohort study","volume":"63","author":"Schr\u00f6ck","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1373\/clinchem.2018.297549","article-title":"Cell-free SHOX2 DNA methylation in blood as a molecular staging parameter for risk stratification in renal cell carcinoma patients: a prospective observational cohort study","volume":"65","author":"Jung","year":"2019","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib10","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41416-018-0035-8","article-title":"Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study","volume":"118","author":"Bergheim","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13148-016-0299-x","article-title":"Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract","volume":"8","author":"Branchi","year":"2016","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib12","first-page":"825","article-title":"Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates","volume":"40","author":"Dietrich","year":"2012","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/gutjnl-2012-304149","article-title":"Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer","volume":"63","author":"Church","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ebiom.2018.03.029","article-title":"Plasma mSEPT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma","volume":"30","author":"Oussalah","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13148-016-0192-7","article-title":"Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites","volume":"8","author":"Jung","year":"2016","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib16","doi-asserted-by":"crossref","first-page":"e84225","DOI":"10.1371\/journal.pone.0084225","article-title":"Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions","volume":"8","author":"Dietrich","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib17","doi-asserted-by":"crossref","first-page":"D754","DOI":"10.1093\/nar\/gkx1098","article-title":"Ensembl 2018","volume":"46","author":"Zerbino","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/978-1-4939-7481-8_32","article-title":"DNA methylation analysis of free-circulating DNA in body fluids","volume":"1708","author":"Jung","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13148-017-0425-4","article-title":"Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients","volume":"9","author":"de Vos","year":"2017","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib20","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/annonc\/mdx125","article-title":"Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients","volume":"28","author":"Vidal","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib21","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/annonc\/mdv177","article-title":"Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer","volume":"26","author":"Tie","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib22","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1158\/1078-0432.CCR-16-3155","article-title":"Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study)","volume":"23","author":"Garlan","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib23","doi-asserted-by":"crossref","first-page":"e1002198","DOI":"10.1371\/journal.pmed.1002198","article-title":"Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study","volume":"13","author":"Parkinson","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib24","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood-2016-09-740308","article-title":"Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes","volume":"129","author":"Yeh","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib25","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/ijc.30650","article-title":"Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients","volume":"140","author":"Cheng","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib26","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1038\/s41598-017-08297-z","article-title":"Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer","volume":"7","author":"Del Re","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib27","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/1878-0261.12305","article-title":"Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer","volume":"12","author":"Kodahl","year":"2018","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib29","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41467-018-03215-x","article-title":"Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer","volume":"9","author":"O'Leary","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib30","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1373\/clinchem.2017.281543","article-title":"Liquid profiling of circulating tumor DNA in plasma of melanoma patients for companion diagnostics and monitoring of BRAF inhibitor therapy","volume":"64","author":"Haselmann","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib31","doi-asserted-by":"crossref","first-page":"11198","DOI":"10.1038\/srep11198","article-title":"Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations","volume":"5","author":"Tsao","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1373\/clinchem.2014.230235","article-title":"Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors","volume":"61","author":"Sanmamed","year":"2015","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib33","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/annonc\/mdx212","article-title":"Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study","volume":"28","author":"Cabel","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib34","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","article-title":"Early reduction in ctDNA predicts survival in lung and bladder cancer patients treated with durvalumab","volume":"24","author":"Raja","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib35","doi-asserted-by":"crossref","first-page":"e1424675","DOI":"10.1080\/2162402X.2018.1424675","article-title":"Circulating tumor DNA evaluated by next-generation sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer","volume":"7","author":"Giroux Leprieur","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib36","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","article-title":"Early assessment of lung cancer immunotherapy response via circulating tumor DNA","volume":"24","author":"Goldberg","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib37","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1158\/1078-0432.CCR-16-0613","article-title":"Circulating tumor DNA as an early indicator of response to T-cell transfer immunotherapy in metastatic melanoma","volume":"22","author":"Xi","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib38","doi-asserted-by":"crossref","first-page":"33505","DOI":"10.1038\/srep33505","article-title":"Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients","volume":"6","author":"Riediger","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib39","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1373\/clinchem.2016.261834","article-title":"Next generation sequencing of circulating cell-free DNA for evaluating mutations and gene amplification in metastatic breast cancer","volume":"63","author":"Page","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib40","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1158\/2159-8290.CD-15-0399","article-title":"Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor","volume":"5","author":"Piotrowska","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib41","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1530\/ERC-15-0369","article-title":"Methylated circulating tumor DNA in blood: power in cancer prognosis and response","volume":"23","author":"Warton","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/biom6040045","article-title":"The emergence of pan-cancer CIMP and its elusive interpretation","volume":"6","author":"Miller","year":"2016","journal-title":"Biomolecules"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib43","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.2015.66.2080","article-title":"Monitoring of serum DNA methylation as an early independent marker of response and survival in metastatic breast cancer: TBCRC 005 prospective biomarker study","volume":"35","author":"Visvanathan","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-1-4939-7234-0_18","article-title":"DNA methylation analysis from body fluids","volume":"1655","author":"Dietrich","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib45","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/SLA.0000000000002901","article-title":"Circulating free methylated tumor DNA markers for sensitive assessment of tumor burden and early response monitoring in patients receiving systemic chemotherapy for colorectal cancer liver metastasis","volume":"268","author":"Bhangu","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib46","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1158\/1078-0432.CCR-17-0291","article-title":"Development and validation of an ultradeep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer","volume":"23","author":"Janku","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib47","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib48","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/ijc.30625","article-title":"Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer","volume":"140","author":"Herbst","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib49","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/bjc.2014.463","article-title":"Methylated glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer","volume":"111","author":"Mahon","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib50","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1311194","article-title":"Multitarget stool DNA testing for colorectal-cancer screening","volume":"370","author":"Imperiale","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2020.04.205_bib51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/35094077","article-title":"Rescuing the function of mutant p53","volume":"1","author":"Bullock","year":"2001","journal-title":"Nat Rev Cancer"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157820302993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157820302993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:14:18Z","timestamp":1761502458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157820302993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1525157820302993"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2020.04.205","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2020.04.205","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}